Car T Kymriah denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for car t kymriah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Step-Therapy Requirements to Kymriah

Step-therapy (also called "fail-first") policies require patients to try one or more lower-cost or more-established treatments before the insurer will approve a higher-tier therapy. For Kymriah (tisagenlecleucel), UnitedHealthcare's coverage policy typically specifies a prior-lines-of-therapy requirement — meaning the patient must have received and failed a defined sequence of prior treatments before CAR-T is authorized. Denials occur when the documentation of prior therapy is incomplete, when the prior regimens are not the ones specified in the policy, or when the chart does not clearly document failure or intolerance.

## Why This Denial Is Appealable

Step-therapy denials are highly document-driven and frequently overturned when complete treatment records are submitted. If the patient has already completed the required prior lines of therapy — as is usually the case by the time CAR-T is being considered — the denial is a documentation gap, not a clinical gap. Step-therapy override laws in many states also provide additional grounds: if completing additional steps would cause irreversible harm, or if the required step has already failed, the insurer must grant an exception.

## Federal Appeal Framework

• Internal appeal: File within the Explanation of Benefits deadline. Lead with a chronological summary of prior therapy history.
• Step-therapy exception request: File simultaneously if your state has a step-therapy override law (most states do); include a prescriber attestation that further step-therapy would harm the patient or is clinically contraindicated.
• Expedited review: Available when delay would seriously jeopardize health — relevant here given disease progression risk.
• External Independent Review (ACA §2719): Available after internal exhaustion; IRO decision is binding.
• ERISA §503: Full-and-fair review for employer plans; approximately four-month external-review window.

## Documentation to Gather

1. Prior-therapy chronology — a table listing every prior regimen with start date, end date, best response, and reason for discontinuation (progression, relapse, or intolerance). 2. Source records for each prior line — oncology notes, response assessments, imaging reports, or lab values corroborating each entry in the chronology. 3. Prescriber medical-necessity letter — explicitly addressing each prior-therapy requirement in UHC's policy and confirming the patient has satisfied it. 4. Current disease documentation — most recent staging or disease-burden assessment confirming ongoing need. 5. Applicable guideline reference — a citation to the applicable professional society guideline (e.g., the applicable NCCN guideline) confirming that CAR-T is the recognized next step for this patient's disease state.

## Criteria-Mapping Structure

Obtain UHC's current coverage policy for tisagenlecleucel and identify every prior-therapy requirement. Build a table: left column — each required prior therapy or step; right column — the chart documentation (dates, regimen name, response, and discontinuation reason) proving that step was completed. Any gap in the right column is an appeal risk; close it before submitting. Attach the source records as indexed exhibits.